NIH's NIAAA initiates clinical trial of Horizant to treat alcohol use disorder

The US National Institutes of Health's (NIH) National Institute on Alcohol Abuse and Alcoholism (NIAAA) has initiated a clinical trial of Horizant (gabapentin enacarbil) extended-release tablets to treat patients with moderate to severe alcohol use d…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news